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Conclusion: Many physicians reported use of class I AAD for the treatment
of post-MI patients with asymptomatic VPD in spite of the CAST findings.
This survey suggests that more effective methods of dissemination of clinical
trials results are needed.
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The Cost-Effectiveness of Pravastatin in Secondary
Prevention of Coronary Heart Disease
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Care of Acute Myocardial Infarction by Non-invasive
and Invasive Cardiologists: Procedure Use, Cost,
and Outcome
Thomas G. Di Salvo, Sumita D. Paul, Conrad A. Smith, Michael!. Miyamoto,
Donald lIoyd-Jones, Kim A. Eagle, Patrick T. O'Gara Massachusetts General Hospital
and Harvard Medical School, Boston, MA
To determine if physician subspecialization influences practice style and
resource utilization, we prospectively studied 292 consecutive emergency
room admissions with MI under the care of noninvasive (NON, n = 213) or
invasive (INV, n = 791 cardiologists and compared the use of cardiac pro-
cedures, cost, and outcome. Results: Patient age, gender, CAD risk factors,
history of angina, MI, CHF, and prior cardiac catheterization, PTCA or CABG
were comparable. Presentation of MI. non-OIQ-wave MI, use of thrombolytic
therapy, peak CK, and EF did not differ. Procedures, cost, and length of stay
were as follows:
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To determine the cost-effectiveness of pravastatin therapy in patients with
coronary heart disease, a projected risk model was developed that used
the results of the three-year, double blind, placebo controlled clinical trials:
Pravastatin Limitation ofAtherosclerosis in the Coronary Arteries (PLAC I) and
Pravastatin, Upids and Atherosclerosis in the Carotid Arteries (PLAC II). In
addition to measuring atherosclerotic progression, the PLAC studies eval-
uated four outcome variables: coronary heart disease death, non-coronary
heart disease death, fatal myocardial infarction, and non-fatal myocardial in-
farction in a patient population (mean age 60 years) with established coro-
nary heart disease and moderate low-density-lipoprotein cholesterol levels,
Pooled PLAC data analysis (n = 559) revealed a statistically significant (p <
0.05) difference in male non-fatal myocardial infarctions between the pravas-
tatin and placebo groups. The projected risk model utilized Framingham data
to project the risk of mortality 10 years post myocardial infarction. Markov
Process was used to estimate the life-years saved and cost. All costs and
benefits were discounted by 5%, Results are presented in the table below:
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Cost per Life-Year Saved
$19,082
$14,022
$10,630
Clinical and Economic Studies of PTCA
Patient Risk Profile
Male with CHD + 1Additional Risk Factor
Male with CHD + 2 Additional Risk Factors
Male with CHD + 3 Additional Risk Factors
Based on this model, pravastatin monotherapy in secondary prevention of
coronary heart disease has a cost-effectiveness ratio comparable to some of
the widely accepted medical interventions such as breast cancer screening,
$21,700, hydrochlorothiazide in the treatment of hypertension, $16,400, and
pneumococcal vaccine, $12,000.
Influence of Platelet GP lib/ilia Receptor
Inhibition with c7E3 on the Sequelae of
Dissection During Percutaneous Coronary
Revascularization
A. Michael Lincoff, Eric J. Topol, Robert M, Califf, Harlan F. Weisman, Nancy
M. Wildermann, Stephen G. Ellis. The Cleveland Clinic Foundation, Cleveland, OH;
Duke University. Durham, NC
The EPIC Trial tested the efficacy of the c7E3 monoclonal antibody to the
platelet GP IIblllla receptor in preventing ischemic events during "high-risk"
PTCA or atherectomy by randomizing 2099 pts to receive placebo (PL), c7E3
bolus (BO), or c7E3 bolus + 12 hr infusion (BO + IN). BO + IN of c7E3 pro-
duced a 35% reduction in the 30-day composite primary endpoint (death, MI,
urgent CABG, or re-PTCA) from 12.8% to 8.3% (p = 0,009) compared with
placebo. Although c7E3 would not be expected to prevent the mechanical
complication of coronary dissection, this agent may limit subsequent throm-
bus formation at dissection sites and thereby prevent progression to overt
closure, embolization, or ischemic clinical events.
The influence of c7E3 on adverse sequelae among pts who sustained dis-
section during EPIC was therefore investigated. Moderate (2-10 mm) or long
I> 10 mm) dissections, as determined by Angiographic Core Laboratory anal-
ysis, occurred in 40.1 %, 39,3%, and 42.5% of pts randomized to PL, BO, or
BO + IN, respectively.
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NON INV p-value
Thall Ell (%) 45 36 NS
Catheterization (%) 59 67 NS
CABG (all pts, %) 13 12 NS
PTCA (3VD, %) 17 35 NS
PTCA (1 or 2-VD, %) 39 60 <0.05
Total hospital days 14 17 <005
ICU days 31 5.4 <001
Hospital costs 1$) 19,400 25,500 0.01
Background: High plasma homocysteine concentration is a significant risk
factor for premature vascular disease in men, but the role in determining
coronary disease risk in women remains unclear.
Methods: Risk factors, including hypertension, hypercholesterolemia,
smoking, and diabetes were recorded in 228 patients (175 men, 53 women)
with angiographically documented coronary disease (2:70% stenosis of at
least one major coronary vessel), and 223 healthy controls (181 men, 42
women), Fasting total plasma homocysteine was measured in all subjects.
A high homocysteine concentrations was defined as a level greater than the
80th percentile, adjusted for gender.
Results: In univariate analysis, homocysteine correlated with age, but not
smoking, hypertension or hypercholesterolemia. Homocysteine values and
odds ratios based upon multivariate analysis were:
There were no differences between groups in the incidence of post-
MI complications (shock, pulmonary edema, post-MI angina, VTNF) or re-
versible thallium perfusion defects. Overall, 61 % of patients underwent car-
diac catheterization; there were an equal number of patients with 1, 2, and
3-vessel CAD in each group. Multivariate predictors of PTCA in patients with
1 or 2-vessel CAD were previous PTCA, Q-wave MI, and care by INV. Out-
come: In-hospital reinfarction and mortality (8.7% vs 12.7%) did not differ;
during median 12-month follow-up (96% of pts), reinfarction and mortality
(11.3% vs 10.3%) were similar, ConClusion: In this pilot study, subspecial-
ization impacted upon the cost of care of MI and led to increased PTCA in
patients with 1 or 2-vessel CAD; larger studies are needed to determine the
influence of subspecialization on long-term clinical outcomes.
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High Homocysteine Concentrations: An Independent
Risk Factor for Coronary Atherosclerosis in Women
Ellen Mayer, Dave Miller, Anjun Gupta, Steven E. Nissen, Donald W. Jacobsen,
Ralph Green, Kandice Kottke Marchant, Killian Robinson. The Cleveland Clinic
FoundaD'on, Cleveland, Ohio
Abrupt Closure 13% 7% 10% 0,080
Embolization < 1% 1% 1% 0.693
Primary Composite Endpoint 17% 12% 10% 0025
Death 3% 1% 1% 0.510
Myocardial Infarction 12% 6% 7% 0013
Emergency Re-PTCA 6% 5% 1% 0002
Emergency CABG 5% 3% 3% 0.350
Women Men
Patients Controls Patients Controls
Age 62 ± 12' 53 ± 10 61 ± 11' 51 ± 10
Homocysteine Levell/lmol!L) 127 ± 4.4' 102 ± 4.9 13.1 ± 4.3' 11.3 ± 30
Percent High Homocysteine 55,t 20 35' 20
Odds Ratio 3.2' NA 1.9' NA
Confidence Interval 1.2-£.4 NA 11-33 NA
* p < 0.01 V$ controls; t p < 0.05 vs male patients
Event PL (N = 278) BO IN = 273) BO + IN IN ~ 301) p-value
Conclusions: Mean homocysteine concentrations are higher in women
with coronary disease than age and sex matched controls. High homocys-
teine levels are more frequently seen in women than men and confer an
independent three-fold incremental risk of CAD.
Although c7E3 did not significantly diminish the risk of abrupt closure or
embolization among pts with moderate or long coronary dissections, potent
reduction in the incidences of MI and emergency repeat revascularization
may reflect ultimate stabilization of disrupted vascular segments during the
